Choices of methodology in pharmacoeconomic studies

Medical Care

Volumn 37, Issue 4 SUPPL. 1, 1999, Pages

  Longo, Christopher J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cost benefit analysis; Cytoprotective; Pharmacoeconomic guidelines; Pharmacoeconomics; Willingness to pay (WTP)

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; RADIOPROTECTIVE AGENT;

ARTICLE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH PERSONNEL ATTITUDE; HEALTH SERVICES RESEARCH; HUMAN; METHODOLOGY; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY TUMOR; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

AMIFOSTINE; ANTINEOPLASTIC AGENTS, ALKYLATING; ATTITUDE OF HEALTH PERSONNEL; CANADA; CISPLATIN; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MULTICENTER STUDIES; NEUTROPENIA; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIATION-PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0033111647     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199904001-00006     Document Type: Article

References (8)

1. Kemp G, Rose F, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101.
2. O'Brien B, Gafni A. When do the "dollars" make sense? Toward a conceptual frame-work for contingent valuation studies in health care. Med Decis Making 1996;16:288.
3. Dranitsaris G, Altmayer C, Quirt I. Cost-benefit analysis of prophylactic granulocyte colony stimulating factor during CHOP antineoplastic therapy for non-hodgkin's lymphoma. Pharmacoecon 1997;11:566.
4. Berwick DM, Weinstein MC. What do patients value? Willingness to pay for ultrasound in normal pregnancy. Med Care 1985;23:881.
5. Estaugh SR. Valuation of the benefits of risk-free blood: Willingness to pay for hemoglobin solutions. Int J Technol Assess Health Care 1991;7(1):51.
6. Johannesson M, Jonsson B, Borquist L. Willingness to pay for antihypertensive therapy - results of a Swedish pilot study. J Health Econ 1991;10:461.
7. Kartman B, Anderson F, Johannesson M. Willingness to pay for reductions in angina pectoris attacks. Med Decis Making 1996;16:248.
8. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Supportive Care Cancer 1997; 5:489.